Medford Biotech Firm Receives $20 Million

Dustin Armstrong, VP and Head of Research for 4s3 Bioscience, with Dr. Susan Windham-Bannister, President & CEO of the Massachusetts Life Sciences Center, which awarded a loan for research to the company in 2010. Courtesy photo.

4s3 Bioscience, Inc., a privately-held biotherapeutics company that develops genetic disease therapies for orphan neuromuscular disorders, has closed on a $20 million round of Series A financing with KLP Enterprises, LLP, according to a press release from 4s3.

KLP’s subsidiary, Alopexx Enterprises, LLC will work with 4s3 to build and manage the company. The money will be used to continue development of a proprietary antibody technology that provides targeted and active intracellular delivery of active proteins, enzymes and other macromolecules to skeletal muscle. The technology enables the replacement of deficient proteins to skeletal muscle, which could be used to treat the underlying causes of muscular dystrophies, myopathies, motor neuron diseases, diseases of the neuromuscular junction and various enzyme deficiency disorders.

4s3 Bioscience, Inc. Is a Medford, Massachusetts biotherapeutics company focused on the targeted delivery of therapeutics to skeletal muscle tissue, promising technology for those afflicted by various muscular diseases. The company was founded in 2007 by Dustin Armstrong and Timothy Harris based on the research of Richard Weisbart, PhD.

– InsideMedford.com